ABN Amro Investment Solutions Has $597,000 Stake in Alnylam Pharmaceuticals, Inc. $ALNY

ABN Amro Investment Solutions trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 99.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,310 shares of the biopharmaceutical company’s stock after selling 200,000 shares during the quarter. ABN Amro Investment Solutions’ holdings in Alnylam Pharmaceuticals were worth $597,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth about $25,000. Salomon & Ludwin LLC bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $27,000. ORG Partners LLC grew its position in shares of Alnylam Pharmaceuticals by 70.2% during the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 33 shares during the period. Quent Capital LLC acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $39,000. Finally, Hilltop National Bank bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at about $41,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling

In other news, EVP Jeffrey V. Poulton sold 2,780 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $1,008,778.60. Following the transaction, the executive vice president directly owned 57,465 shares of the company’s stock, valued at $20,852,324.55. The trade was a 4.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total value of $848,055.70. Following the transaction, the executive vice president owned 21,264 shares in the company, valued at $7,874,697.12. The trade was a 9.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 19,177 shares of company stock valued at $6,975,746 over the last 90 days. 1.20% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $314.40 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The stock has a market capitalization of $41.70 billion, a price-to-earnings ratio of 183.86 and a beta of 0.35. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The company’s 50 day simple moving average is $372.67 and its 200 day simple moving average is $424.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the previous year, the firm posted ($0.65) EPS. The firm’s revenue was up 84.9% compared to the same quarter last year. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ALNY. Raymond James Financial reiterated an “outperform” rating and set a $472.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Truist Financial reduced their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Oppenheimer assumed coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective on the stock. Needham & Company LLC cut their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Finally, Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Twenty-two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $477.38.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.